Genmab A/S

434 articles about Genmab A/S

• EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

  5/19/2023

  Genmab A/S announced that the U.S. Food and Drug Administration has approved EPKINLY™ as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B‑cell lymphoma, after two or more lines of systemic therapy.

• Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen

  4/20/2023

  Genmab A/S (Nasdaq:GMAB) announced today an award in the second arbitration arising under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab.

• Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023

  4/18/2023

  Genmab A/S announced that worldwide net trade sales of DARZALEX®, including sales of the subcutaneous product, as reported by Johnson & Johnson were USD 2,264 million in the first quarter of 2023.

• Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

  4/17/2023

  Genmab A/S and argenx announced that Genmab and argenx have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas.

• argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

  4/17/2023

  argenx SE and Genmab A/S announced that argenx and Genmab have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas.

• Genmab Publishes 2022 Annual Report

  2/22/2023

  Genmab A/S announced the publication of its Annual Report for 2022.

• Genmab Announces Initiation of Share Buy-Back Program - February 22, 2023

  2/22/2023

  Genmab A/S announced that it is initiating a share buy-back program to honor our commitments under our Restricted Stock Unit program.

• Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022

  1/24/2023

  Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 7,977 million in 2022.

• Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

  12/21/2022

  Genmab A/S (Nasdaq: GMAB) today announced that the company has submitted a Japan new drug application (JNDA) to the Ministry of Health, Labor and Welfare (MHLW) of Japan for subcutaneous epcoritamab (DuoBody®-CD3xCD20), an investigational bispecific antibody, for the treatment of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy.

• Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

  12/11/2022

  Genmab A/S announced the results from multiple clinical trials evaluating epcoritamab, an investigational subcutaneous bispecific antibody.

• Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

  11/21/2022

  Genmab A/S today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for subcutaneous epcoritamab (DuoBody®-CD3xCD20).

• Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)

  11/3/2022

  Genmab A/S (Nasdaq: GMAB) announced today that 19 abstracts evaluating various investigational medicines in its pipeline have been accepted for presentation at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH), being held at the Ernest N. Morial Convention Center in New Orleans, Louisiana, and virtually, December 10-13.

• Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)

  10/28/2022

  Genmab has Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for epcoritamab.

• Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022

  10/18/2022

  Genmab A/S announced that worldwide net trade sales of DARZALEX®,including sales of the subcutaneous product,as reported by Johnson & Johnson were USD 2,052 million in the third quarter of 2022.

• Major Shareholder Announcement - October 05, 2022

  10/5/2022

  Genmab A/S announces under reference to Section 30 of the Danish Capital Markets Act that Wellington Management Group LLP has informed us that, as of October 4, 2022, Wellington Management Group LLPthrough shares and financial instruments holds the voting rights to 3,309,527 shares in Genmab A/S, which amounts to 5.03% of the share capital and voting rights in Genmab A/S.

• Genmab Announces Financial Results for the First Half of 2022

  8/10/2022

  Genmab Announces Financial Results for the First Half of 2022.

• Genmab Improves Its 2022 Financial Guidance

  8/8/2022

  Genmab A/S announced that it is improving its 2022 financial guidance published on May 11, 2022.

• Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates

  8/5/2022

  Genmab A/S (Nasdaq: GMAB) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced an expansion of their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients.

• BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates

  8/5/2022

  BioNTech SE and Genmab A/S announced an expansion of their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients.

• Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2022

  7/19/2022

  COPENHAGEN, Denmark; July 19, 2022 – Genmab A/S announced that worldwide net trade sales of DARZALEX®,including sales of the subcutaneous formulation,as reported by Johnson & Johnson were USD 1,986 million in the second quarter of 2022.